Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort
| Autor: | Zaliani, Andrea, Vangeel, Laura, Reinshagen, Jeanette, Iaconis, Daniela, Kuzikov, Maria, Keminer, Oliver, Wolf, Markus, Ellinger, Bernhard, Esposito, Francesca, Corona, Angela, Tramontano, Enzo, Manelfi, Candida, Herzog, Katja, Jochmans, Dirk, De Jonghe, Steven, Chiu, Winston, Francken, Thibault, Schepers, Joost, Collard, Caroline, Abbasi, Kayvan, Claussen, Carsten, Summa, Vincenzo, Beccari, Andrea R., Neyts, Johan, Gribbon, Philip, Leyssen, Pieter |
|---|---|
| Přispěvatelé: | Publica, Zaliani, Andrea, Vangeel, Laura, Reinshagen, Jeanette, Iaconis, Daniela, Kuzikov, Maria, Keminer, Oliver, Wolf, Marku, Ellinger, Bernhard, Esposito, Francesca, Corona, Angela, Tramontano, Enzo, Manelfi, Candida, Herzog, Katja, Jochmans, Dirk, De Jonghe, Steven, Chiu, Winston, Francken, Thibault, Schepers, Joost, Collard, Caroline, Abbasi, Kayvan, Clausses, Carsten, Summa, Vincenzo, Beccari, Andrea R., Neyts, Johan, Gribbon, Philip, Leyssen, Pieter |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Popis: | Worldwide, there are intensive efforts to identify repurposed drugs as potential therapies against SARS-CoV-2 infection and the associated COVID-19 disease. To date, the anti-inflammatory drug dexamethasone and (to a lesser extent) the RNA-polymerase inhibitor remdesivir have been shown to be effective in reducing mortality and patient time to recovery, respectively, in patients. Here, we report the results of a phenotypic screening campaign within an EU-funded project (H2020-EXSCALATE4COV) aimed at extending the repertoire of anti-COVID therapeutics through repurposing of available compounds and highlighting compounds with new mechanisms of action against viral infection. We screened 8702 molecules from different repurposing libraries, to reveal 110 compounds with an anti-cytopathic IC50 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|